טוען...
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of cho...
שמור ב:
| Main Authors: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2770422/ https://ncbi.nlm.nih.gov/pubmed/19920956 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|